Myriad, PharmaMar Enter CDx Agreement for HRD Test | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics will conduct homologous recombination deficiency (HRD) testing on patients enrolled in PharmaMar's Phase II clinical study for its anti-tumor drug candidate under a deal announced after the close of the market on Tuesday.

Myriad said it will conduct HRD testing for patients in a clinical study for PM1183, PharmaMar's drug candidate that induces double-stranded DNA breaks to cause cell death. The partnership, Myriad said, is the first publicly announced commercial deal covering its new HRD test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.